- Home
- GUTS vs KRON Comparison
GUTS vs KRON Comparison
Compare GUTS & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- KRON
- Stock Information
- Founded
- GUTS 2010
- KRON 2017
- Country
- GUTS United States
- KRON United States
- Employees
- GUTS N/A
- KRON N/A
- Industry
- GUTS
- KRON Medicinal Chemicals and Botanical Products
- Sector
- GUTS
- KRON Health Care
- Exchange
- GUTS NYSE
- KRON Nasdaq
- Market Cap
- GUTS 58.9M
- KRON 61.5M
- IPO Year
- GUTS 2024
- KRON 2020
- Fundamental
- Price
- GUTS $1.12
- KRON $0.81
- Analyst Decision
- GUTS Buy
- KRON Buy
- Analyst Count
- GUTS 1
- KRON 3
- Target Price
- GUTS $10.00
- KRON $1.63
- AVG Volume (30 Days)
- GUTS 201.2K
- KRON 165.9K
- Earning Date
- GUTS 03-03-2025
- KRON 03-18-2025
- Dividend Yield
- GUTS N/A
- KRON N/A
- EPS Growth
- GUTS N/A
- KRON N/A
- EPS
- GUTS N/A
- KRON N/A
- Revenue
- GUTS $93,000.00
- KRON $9,848,000.00
- Revenue This Year
- GUTS N/A
- KRON N/A
- Revenue Next Year
- GUTS N/A
- KRON N/A
- P/E Ratio
- GUTS N/A
- KRON N/A
- Revenue Growth
- GUTS N/A
- KRON 56.62
- 52 Week Low
- GUTS $1.16
- KRON $0.69
- 52 Week High
- GUTS $7.89
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- GUTS 35.75
- KRON 33.06
- Support Level
- GUTS $1.19
- KRON $0.82
- Resistance Level
- GUTS $1.32
- KRON $0.89
- Average True Range (ATR)
- GUTS 0.09
- KRON 0.06
- MACD
- GUTS 0.00
- KRON -0.01
- Stochastic Oscillator
- GUTS 9.09
- KRON 12.63
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.